Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Hammer

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
JAMA|August 15, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|October 5, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
JAMA|July 14, 2004
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Martin S Hirsch, et al.
JAMA|July 4, 2002
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer, Florin Vaida, Kara K Bennett, et al.
JAMA|July 4, 2002
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Charles C J Carpenter, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
JAMA|August 15, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|October 5, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
JAMA|July 14, 2004
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Martin S Hirsch, et al.
JAMA|July 4, 2002
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer, Florin Vaida, Kara K Bennett, et al.
JAMA|July 4, 2002
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Charles C J Carpenter, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
Pageof 9